Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Preliminary results from a phase 2 clinical study suggest that NS002, an investigational intranasal epinephrine powder developed by Nasus Pharma, may offer rapid and robust epinephrine exposure compared with standard intramuscular autoinjector therapy.

The findings, announced on January 20, 2026, showed that NS002 achieved faster absorption and higher peak plasma concentrations, potentially addressing a critical clinical need in the management of

“We believe these interim results are highly encouraging and reinforce the potential of NS002 as a meaningful advancement in anaphylaxis treatment," said Michael Blaiss, MD, clinical professor of allergy and immunology at the Medical College of Georgia at Augusta University and member of Nasus Pharma's Scientific Advisory Board, in a statement.

 “In anaphylaxis, outcomes are highly time-dependent, and delays in achieving effective pharmacologic action are associated with increased mortality. These pharmacokinetic advantages, combined with the needle-free administration, could help address the significant compliance challenges we see with current treatments."

In this open-label, healthy volunteer study, NS002 demonstrated a mean peak plasma concentration (Cmax) of 655 pg/mL versus 548 pg/mL with EpiPen, with time to peak concentration (Tmax) occurring at 10.8 minutes compared to 15 minutes for the autoinjector. Additionally, 91% of participants administered NS002 surpassed the therapeutic plasma threshold of 100 pg/mL within 5 minutes, compared with 67% with EpiPen. Early exposure, measured by area under the concentration-time curve (AUC) over the first 10 minutes, was also greater for NS002 (55 hpg/mL vs 32 hpg/mL), underscoring its potential for quicker pharmacologic action during acute allergic emergencies.

The study enrolled 50 healthy adults with allergic rhinitis across 2 cohorts to assess single and repeat dosing with and without a nasal allergic challenge, simulating real-world anaphylactic conditions. NS002 was well-tolerated with no serious adverse events, and the pharmacodynamic responses (blood pressure, pulse rate) were comparable to the intramuscular standard of care.

These interim results align with published data suggesting powder-based intranasal epinephrine formulations can improve early drug absorption and stability compared with liquid autoinjectors. Prior research involving a smaller cohort demonstrated similar rapid attainment of therapeutic plasma levels with NS002 and highlighted its potential as a needle-free, patient-friendly alternative to traditional epinephrine delivery.

The development of needle-free epinephrine alternatives comes amid broader innovation in anaphylaxis management. For example, ARS Pharmaceuticals’ 

epinephrine nasal spray (neffy) received expanded FDA approval

 in 2025 for use in younger pediatric patients (15–30 kg), reflecting growing interest in non-injectable epinephrine delivery systems.

Anaphylaxis remains a rapidly progressive, potentially fatal type I hypersensitivity reaction in which prompt administration of epinephrine can be lifesaving. Clinicians recognize that treatment delays, hesitation due to needle phobia, and device complexity are barriers to optimal care—challenges that intranasal approaches aim to mitigate.

"We are extremely pleased with these positive interim results, which we believe further validate NS002's potential as a first-in-class intranasal powder epinephrine product for patients with severe allergies," said Dan Teleman, chief executive officer of Nasus Pharma, in a statement.

 "The sustained performance of NS002 across single and repeat dosing scenarios – including under conditions simulating real-world allergic reactions – demonstrates the robustness of our proprietary Nasax® platform technology. We look forward to completing the Phase 2 study and advancing to our pivotal clinical program."

Nasus Pharma plans to complete the full Phase 2 analysis by late Q1 2026 and to initiate a pivotal study in Q4 2026.

Nasus Pharma, Ltd. Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder. GlobeNewswire News Room. Published January 20, 2026. Accessed January 20, 2026. 

https://www.globenewswire.com/news-release/2026/01/20/3221623/0/en/Nasus-Pharma-Announces-Positive-Interim-Results-from-Phase-2-Clinical-Study-of-NS002-Intranasal-Epinephrine-Powder.html

Nasus Pharma. Nasus Pharma Announces Publication Of Its Positive Clinical Results With FMXIN002 Intranasal Powder Epinephrine Spray In The Journal Of Allergy And Clinical Immunology In Practice. Prnewswire.com. Published August 8, 2023. Accessed January 20, 2026. 

https://www.prnewswire.com/news-releases/nasus-pharma-announces-publication-of-its-positive-clinical-results-with-fmxin002-intranasal-powder-epinephrine-spray-in-the-journal-of-allergy-and-clinical-immunology-in-practice-301895372.html?utm_source=chatgpt.com

Campbell P. FDA Approves 1 mg neffy Nasal Spray for Pediatric Anaphylaxis. Hcplive.com. Published March 6, 2025. Accessed January 20, 2026. 

https://www.hcplive.com/view/fda-approves-1-mg-neffy-nasal-spray-for-pediatric-anaphylaxis

Greenhawt M, Schroer B, Kraft C, et al. One Year Later: How Intranasal Epinephrine Is Changing Emergency Allergy Treatment. Hcplive.com. Published August 8, 2025. 

https://www.hcplive.com/view/one-year-later-how-intranasal-epinephrine-is-changing-emergency-allergy-treatment

Articles

Preliminary findings from a phase 2 study indicate that NS002, an investigational intranasal epinephrine powder, may provide faster and more robust epinephrine exposure than traditional intramuscular autoinjectors. NS002 demonstrated quicker absorption and higher peak plasma concentrations, potentially addressing critical needs in anaphylaxis management. The study involved 50 healthy adults and showed NS002 was well-tolerated with no serious adverse events. These results support the potential of NS002 as a needle-free alternative, aligning with broader innovations in anaphylaxis treatment and addressing compliance challenges associated with current therapies.

Interim phase 2 results show NS002 delivered faster absorption and greater early epinephrine exposure than EpiPen, with comparable safety and tolerability.


News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Phase 2 Data Show NS002 Intranasal Epinephrine Acts Faster Than EpiPen

Sonalika Khachikian, MD, is an endocrinologist at Monument Health.

Emerging Biologic Targets and Disease Heterogeneity in TED

Rapid advances in immunology are expanding the therapeutic landscape for thyroid eye disease beyond first-in-class IGF-1 receptor inhibition.

In this video, Sonalika Khachikian, MD, an endocrinologist at Monument Health Hospital in South Dakota, anticipates the development of additional IGF-1R–directed therapies with varying molecular properties and dosing schedules, noting that increased competition may broaden treatment options and improve access.

Beyond IGF-1R, Khachikian highlights alternative inflammatory pathways under investigation, including interleukin 6 inhibition and neonatal Fc receptor blockade. Drawing parallels to rheumatologic disease management, she suggests these agents may be particularly useful in patients whose disease phenotype is dominated by inflammatory symptoms rather than structural orbital changes. Such therapies may serve as adjuncts or induction strategies, though infection risk and systemic safety will require careful consideration.

She underscores the heterogeneity of TED, observing that while many patients respond durably to biologic therapy, others experience relapse or fluctuating disease activity. These patterns remain incompletely understood and were the subject of ongoing discussion at recent scientific meetings, including the American Thyroid Association. Her comments highlight the need for continued research to refine long-term management strategies.

Videos

Video Series

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Liver Transplant Access in the MELD 3.0 Era: Progress, Limitations, and Lingering Gaps

As liver transplantation continues to evolve, so too does the scoring system that determines which patients receive access to life-saving organs. In this segment of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD, and Nancy Reau, MD, unpack new data examining MELD 3.0 and whether it meaningfully addressed long-standing inequities in transplant access, particularly for women and other disadvantaged patient groups.

Check out the full episode on advances in liver transplantation and hepatocellular carcinoma 

Brown opened the discussion by providing context on why MELD 3.0 was developed in the first place. She notes that the MELD score has been repeatedly refined over time, including the addition of serum sodium, in response to concerns that certain patient populations may be unfairly advantaged or disadvantaged.

One of the most prominent concerns, she explains, relates to sex-based differences, largely because serum creatinine is influenced by muscle mass. Because women generally have lower muscle mass than men, Brown emphasizes that they may receive artificially lower MELD scores despite similar disease severity.

She and Reau walk through the design of a study presented at the 

American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025

, which analyzed OPTN data from > 60,000 adult liver transplant candidates between 2020 and 2024, 40% of whom were women. Investigators focused on transplant access, including receipt of a top-5 organ offer and the likelihood of undergoing deceased donor liver transplantation, although Brown cautioned that MELD was originally designed to predict mortality rather than organ offers, a distinction she urges listeners to keep in mind when interpreting the results.

Brown explains that during the MELD 3.0 “burn-in” period, women experienced a significant increase in top-5 offers and transplant rates compared with men. However, she notes that this improvement was not sustained over time, with odds ratios eventually returning to pre-implementation levels, echoing prior discussions suggesting that height and overall size may play a larger role than sex alone.

Reau builds on this observation, highlighting the practical challenges of transplanting very small patients, noting that size mismatch often leads surgeons to decline offers. While women are more frequently affected, she emphasizes that very small men face similar barriers.

Both experts agree that while MELD 3.0 represented progress, it did not fully resolve structural inequities. Brown acknowledges that factors such as age and height continue to influence access, while Reau underscores the importance of maintaining a dynamic scoring system that can adapt to changing indications and patient populations.

Editors’ note: Relevant Disclosures for Reau include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

Tanaka T, Shane D, Lai J. MELD 3.0 Failed to Sustainably Address Sex Disparities in US Liver Transplant Allocation. Presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025. Washington, DC. November 7-11, 2025.

This segment of Liver Lineup features an in-depth discussion on transplant access with MELD 3.0 and new research about potential disparities it introduces.

Hepatology

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Susan Weiner, MS, is a diabetes care and education specialist and the founder and owner of Susan Weiner Nutrition, PLLC.

US 2025-2030 Dietary Guidelines: Addressing Alcohol Intake Recommendations

The US Department of Health and Human Services and the US Department of Agriculture released the 2025-2030 Dietary Guidelines for Americans on January 7, 2026. Along with establishing the first-ever limit on processed foods, firmly encouraging a focus on whole foods, and recommending a higher proportion of protein, the guidelines come with several uncertainties and limitations.

Prominent among these uncertainties is a significantly broader suggestion of how people should manage their alcohol intake. Rather than explicitly stating a recommended number of drinks, the guidelines now advise patients to limit their alcohol intake. To address and attempt to explain this vague suggestion, Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, met with Susan Weiner, MS, a nationally recognized dietitian and diabetes care and education specialist.

Check out the full episode on the 2025-2030 Dietary Guidelines for Americans 

Weiner opens by raising substantive concerns about revisions to alcohol-related recommendations in the newly released US dietary guidelines, emphasizing the clinical and policy implications of shifting from quantitative to more ambiguous language. She notes that previous guidelines clearly defined alcohol limits—less than two drinks per day for men and one drink per day for women—while also specifying standard drink sizes and citing evidence linking alcohol consumption to adverse outcomes such as cancer, liver disease, metabolic dysfunction, and other chronic conditions. In contrast, the updated guidance broadly advises individuals to “drink less,” without numerical thresholds, detailed definitions, or accompanying references to alcohol-related harms. Weiner argues that this lack of specificity reduces the guidance’s practical value for clinicians and increases the risk of misinterpretation by patients, who may rationalize unsafe drinking behaviors under vague recommendations.

The discussion highlights how this ambiguity is particularly concerning in populations with diabetes or alcohol-induced dysglycemia, where alcohol can acutely and chronically disrupt glucose regulation, exacerbate liver disease, and affect multiple organ systems. Bellini reflects on the importance of having firm, evidence-based language that clinicians can reference directly in counseling and documentation, noting that tighter guidance previously served as a useful clinical tool. Bellini expresses worry that the revised wording may be perceived as a loosening of standards, potentially undermining public health messaging at a time when alcohol consumption increased during and after the COVID-19 pandemic.

Beyond individual patient care, the conversation emphasizes that dietary guidelines function as policy instruments. Weiner notes that these recommendations shape nutrition education curricula taught to children, influence school lunch programs, and may affect federal food and nutrition programs such as WIC, SNAP, and even military food services. From this vantage point, changes to alcohol guidance could have broad societal consequences, reinforcing the need for clarity and scientific rigor.

The segment also explores how professional organizations interpret and adopt federal dietary guidelines. Isaacs observes that groups such as the American Heart Association appear to be maintaining more conservative, established recommendations (such as the plate method, emphasis on lean meats, and limiting saturated fats) despite broader inclusions in the new guidelines, including butter and beef tallow. Weiner anticipates that organizations focused on cardiovascular disease, cancer, and metabolic health will publicly scrutinize and potentially challenge the revised alcohol language, given its established links to disease, mental health outcomes, and excess caloric intake. The discussion concludes with the expectation that further debate and guidance from professional societies will emerge, underscoring that alcohol cannot be excluded from clear, evidence-based dietary recommendations.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Weiner reports no relevant disclosures.

Mozaffarian D. The 2025-2030 Dietary Guidelines for Americans. JAMA. Published online January 14, 2026. 

This segment of Diabetes Dialogue spotlights the new guidelines’ broad suggestion regarding alcohol, as well as how organizations may interpret it.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

New data suggest care improvements can be made for patients with skin cancer who have frail skin through collaboration with geriatricians, the use of a geriatric assessment, and an onco-geriatric multidisciplinary team (OMDT).

These results were the conclusion of a recently-published letter to the editor in the Journal of the European Academy of Dermatology and Venereology (JEADV). It was authored by such investigators as Esther Groll, from the University Medical Center Groningen Department of Dermatology.

Groll et al noted the prognostic value of evaluating frailty in a patient’s skin, though the condition is rarely addressed within patient guidelines. Such guidelines, they highlighted, most often prioritize the characteristics of skin cancer tumors instead.

“The University Medical Center Groningen recently introduced a nurse-led frailty assessment to improve care for this population,” the investigators wrote.

 “We investigated how this screening affected treatment choices and time to treatment.”

Although the Comprehensive Geriatric Assessment (CGA) is considered the reference standard for assessing older oncology patients, Groll and colleagues pointed to the substantial time and resources needed for the CGA’s use. Consequently, this nurse-led frailty screening program was evaluated in its aim to make improvements to older patient care, specifically among those living with skin cancer. They used a retrospective case–control study design, assessing the program’s effects on treatment decision-making and treatment timelines.

There were 290 patients aged 65 years or older involved in this study, all of whom were described as having head and neck skin malignancies.In specific, the study subjects had either cutaneous squamous cell carcinoma, lentigo maligna, or basal cell carcinoma. 145 of the study subjects were screened for frailty in the timeframe between 2022 - 2023. The study’s outcomes were compared with those of a matched historical control cohort of 145 individuals treated between 2018 - 2019 at the same institution.

Matching was done by Groll and coauthors based on sex, diagnosis, and age. The identification of the study’s control cohort was done via the Netherlands Cancer Registry. Individuals included in the control arm of the analysis were not provided with this frailty screening as part of their course of care. The frailty evaluation was conducted through the use of a shortened geriatric evaluation covering 4 domains:

If a participant was shown to have impairments in 2 or more domains, they would be described as frail. Reviews of treatment plans and decisions related to referrals for CGA by a geriatrician were done by an OMDT. This OMDT was made up of a specialized nurse, a dermatologist, a geriatrician, and a radiotherapist. Assessments in this analysis looked at estimated life expectancy, frailty status, and preferences among patients.

114 of the screened patients were labeled by Groll et al as frail (78.6%). The investigative team pointed to functional and psychocognitive impairments as the most commonly observed contributors to frailty. They found 53.8% were reviewed by the OMDT. Changes to treatment were made in 20.7% of these cases. In 1 notable finding, 83.3% of the treatment changes were described as having involved a shift toward less invasive therapeutic choices.

A strong association was identified between the use the OMDT and treatment modifications (OR 5.85, 95% CI 2.09–16.35, 

 < .001). Additionally, a strong link was identified with the selection of less invasive treatments (OR 0.16, 95% CI 0.05–0.52, 

 = .002). Overall, 17.2% of the subjects screened by Groll and colleagues were referred for a CGA. Among 44% of these individuals, Mohs micrographic surgery was replaced with a less invasive alternative.

In contrast, only 4.8% of those inclucded in the historical cohort were provided with treatment diverging from guideline-based recommendations. This was described by the team as a significant difference versus those involved in the screened cohort (

Those who underwent this frailty screening attended more hospital visits on average (median 6 versus 4, 

 < .001), reported longer median interval to initiation of their treatment compared with those in the control arm (62 versus 41.5 days, 

 < .001), and presented with larger median tumor diameters (14 versus 9 mm, 

 < .001). Overall, frailty screening identified a high prevalence of patient frailty and, via the integration of geriatric expertise and patient-centered considerations, supported the implementation of treatment actions considered less aggressive.

“This aligns with prior research that stresses the importance of shared decision-making and incorporation of comorbidities, functional status and life expectancy to guide care and reduce treatment burden,” Groll and coauthors wrote.

Groll E, Hetényi Z, Rácz E. Personalized care for older skin cancer patients: Impact of frailty screening on treatment decisions. J Eur Acad Dermatol Venereol. 2026 Jan 16. 

van Winden MEC, Garcovich S, Lubeek SFK. Frailty screening in dermato-oncology practice: a modified Delphi study and a systematic review of the literature. J Eur Acad Dermatol Venereol. 2021 Jan;35(1):95-104. doi: 10.1111/jdv.16607. Epub 2020 Jul 1. PMID: 32403174; PMCID: PMC7818261.

Recent findings indicate that integrating geriatric assessments and multidisciplinary teams can enhance care for older skin cancer patients with frail skin. A study involving 290 patients aged 65 and older with head and neck skin malignancies demonstrated that nurse-led frailty screenings influenced treatment decisions, often leading to less invasive options. The study highlighted the importance of considering frailty, functional status, and life expectancy in treatment planning. The use of an onco-geriatric multidisciplinary team was associated with significant treatment modifications and improved patient-centered care.

These data suggest improvement of care for patients with skin cancer and frail skin through geriatrician use, along with a nurse-led geriatric assessment, may be beneficial.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Personalized Care Improvements Identified for Older Patients with Skin Cancer

Michael E. Thase, MD, of the University of Pennsylvania

Lumateperone 42 mg plus antidepressants boosts remission rates and sustains symptom improvement in MDD patients, says Michael E. Thase, MD.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Adjunctive Lumateperone Improves Remission Rates in MDD, With Michael E. Thase, MD

This analysis suggests TYK2 (tyrosine kinase 2) inhibitors may have a dual therapeutic potential to address both skin symptoms of psoriasis and comorbid depressive symptoms.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

TYK2, IL-23 Pathway Treatments Assessed in Psoriasis for Lesions, Depressive Symptoms

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

New CureGN findings and an interview with Andrew Vissing, MD, highlight distinct glomerular disease outcomes in adolescents and young adults compared with pediatric and adult patients


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Unmet Needs of Glomerular Disease in Young Adults, Adolescents With Andrew Vissing, MD

Michael Weintraub, MD, is an assistant professor of medicine in the division of endocrinology at NYU Langone Health.

Weintraub discusses how patients with overweight or obesity, regardless of T2D, will regain weight in varying degrees after discontinuing therapy.

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

GLP-1 Discontinuation Results in Significant Weight Regain, With Michael Weintraub, MD

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

Type 1 Diabetes

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Dementia and Alzheimer Disease

Alzheimer Disease condition center page, resources on the topics of medical news and expert insight into Alzheimer's can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dementa and Alzheimer disease research, treatment, and drug development.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

HCPLive 5 Stories in Under 5: Week of 01/11

In a 26-week head-to-head study, adjunctive seltorexant led to less weight gain and improved insulin sensitivity trends compared with quetiapine XR in MDD with insomnia.


Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

Seltorexant Shows Favorable Metabolic Profile, With Celine Goldberger, MD, PhD

In the final episode, ‘Closing Thoughts on Hypoparathyroidism Management,’ the panelists share their key takeaways from the series discussion on hypoparathyroidism.

Closing Thoughts on Hypoparathyroidism Management

In ‘Emerging Therapies in Hypoparathyroidism,’ our experts delve into three emerging therapies in chronic hypoparathyroidism.



Emerging Therapies in Hypoparathyroidism

In this episode, ‘Value of Medical Advocates for Patients and Educational Resources for Clinicians in Hypoparathyroidism,’ the experts explore the importance of recommending medical advocates or medical alerts to patients as well as educational resources that are available for community providers to better manage hypoparathyroidism.



Value of Medical Advocates for Patients and Educational Resources for Clinicians in Hypoparathyroidism

This episode, titled ‘Multidisciplinary Approaches to Hypoparathyroidism Management,’ features expert endocrinologists discussing the role of multidisciplinary collaboration among endocrinologists, nephrologists, and primary care providers.



Latest News

Phase 2 Data Show NS002 Intranasal Epinephrine Acts Faster Than EpiPen

Emerging Biologic Targets and Disease Heterogeneity in TED

Liver Transplant Access in the MELD 3.0 Era: Progress, Limitations, and Lingering Gaps

US 2025-2030 Dietary Guidelines: Addressing Alcohol Intake Recommendations

Personalized Care Improvements Identified for Older Patients with Skin Cancer